Inactive Instrument

Analyst Reco. BioCardia Inc Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 14	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 01	BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	CI

HC Wainwright Adjusts BioCardia's Price Target to $4 From $9, Keeps Buy Rating	23-09-06	MT
Dawson James Downgrades BioCardia to Neutral From Buy	22-11-11	MT
HC Wainwright Starts BioCardia at Buy With $9 Price Target	21-12-20	MT
BIOCARDIA : Dawson James Downgrades BioCardia to Neutral from Buy	21-04-16	MT

No results for this search